Transcat Inc

Transcat Inc(TRNS)股票分析

$86.310

+4.859 (+5.63%)收盤時

Loading chart…
最高
87.230
開盤
86.390
成交量加權均價
86.05
成交量
228.79K
市值
1.09B
最低
84.611
成交金額
19.69M
企業價值/稅息折舊攤銷前利潤(TTM)
18.29

Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. It is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. It provides periodic onsite services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally.

AI 分析 of Transcat Inc (TRNS)

持有

Transcat Inc is currently a hold. The stock is priced at $80.35, which is below the analyst target of $95, indicating potential upside. However, the RSI is at a low 18.985, suggesting the stock is oversold, which could indicate a buying opportunity, but the recent negative earnings report with a net income drop to -1.1 million in Q3 2026 raises concerns. The forward P/E ratio is high at 50.76, indicating that the stock may be overvalued at this price point.

分析師評級(2)

上檔空間 +15.86%
買進
2 買進
0 持有
0 賣出
目前: 86.31
最低
95.00
平均
100.00
最高
105.00

Northland

2026-08-05

目標價

$95

Market Perform

Northland

2025-10-23

目標價

$95

優於大盤

Lake Street

2025-07-10

目標價

$105

買進

H.C. Wainwright

2025-05-21

目標價

$116

買進

HC Wainwright & Co.

2025-01-29

目標價

$106

強烈買進

估值指標

Transcat Inc(TRNS)目前預期本益比為 50.76,5 年平均預期本益比為 56.25。

預期本益比

合理
5 年均值 P/E
56.25
目前P/E
50.76
高估
67.12
低估
45.38

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.37
目前EV/EBITDA
18.29
高估
23.83
低估
16.91

預期股價營收比

低估
5 年均值 P/S
2.67
目前P/S
1.92
高估
3.32
低估
2.02

Alphio AI 對 TRNS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TRNS

$120.31

情境價格

基

基準

基準 · 50%TRNS

$100.88

情境價格

悲

悲觀

悲觀 · 25%TRNS

$94.39

情境價格

持有 TRNS 的大戶

P

Paradice Investment Management Pty Ltd.

+ 持有TRNS

-1.86%

3個月報酬率

事件時間軸

2026-08-31 (ET)

09:30:00

Transcat Acquires Southeastern Biomedical for $12.8M

2026-06-22 (ET)

09:00:00

Transcat Appoints Roy Simmons as Chief Strategy Officer

2026-05-26 (ET)

19:40:00

Market Optimism Drives Crude Oil Prices Lower

16:10:00

Transcat Q4 Revenue $89.33M, Below Consensus

2026-04-09 (ET)

16:10:00

Transcat Acquires SCM Metrology for Approximately $13 Million

資訊

TRNS 常見問題 —— 由 Alphio AI 解答

Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. It is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. It provides periodic onsite services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally. It operates in the Industrials sector (INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & EL industry).

Transcat Inc is currently a hold. The stock is priced at $80.35, which is below the analyst target of $95, indicating potential upside. However, the RSI is at a low 18.985, suggesting the stock is oversold, which could indicate a buying opportunity, but the recent negative earnings report with a net income drop to -1.1 million in Q3 2026 raises concerns. The forward P/E ratio is high at 50.76, indicating that the stock may be overvalued at this price point.

2 analysts cover TRNS: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 100.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易